Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Alzheimers Res Ther ; 9(1): 98, 2017 Dec 15.
Article in English | MEDLINE | ID: mdl-29246249

ABSTRACT

BACKGROUND: Soluble amyloid-ß (Aß) oligomers are the major toxic substances associated with the pathology of Alzheimer's disease (AD). The ability to measure Aß oligomer levels in the blood would provide simple and minimally invasive tools for AD diagnostics. In the present study, the recently developed Multimer Detection System (MDS) for AD, a new enzyme-linked immunosorbent assay for measuring Aß oligomers selectively, was used to detect Aß oligomers in the plasma of patients with AD and healthy control individuals. METHODS: Twenty-four patients with AD and 37 cognitively normal control individuals underwent extensive clinical evaluations as follows: blood sampling; detailed neuropsychological tests; brain magnetic resonance imaging; cerebrospinal fluid (CSF) measurement of Aß42, phosphorylated tau protein (pTau), and total tau protein (tTau); and 11C-Pittsburgh compound B (PIB) positron emission tomography. Pearson's correlation analyses between the estimations of Aß oligomer levels by MDS and other conventional AD biomarkers (CSF Aß42, pTau, and tTau, as well as PIB standardized uptake value ratio [PIB SUVR]) were conducted. ROC analyses were used to compare the diagnostic performance of each biomarker. RESULTS: The plasma levels of Aß oligomers by MDS were higher in patients with AD than in normal control individuals, and they correlated well with conventional AD biomarkers (levels of Aß oligomers by MDS vs. CSF Aß42, r = -0.443; PIB SUVR, r = 0.430; CSF pTau, r = 0.530; CSF tTau, r = 0.604). The sensitivity and specificity of detecting plasma Aß oligomers by MDS for differentiating AD from the normal controls were 78.3% and 86.5%, respectively. The AUC for plasma Aß oligomers by MDS was 0.844, which was not significantly different from the AUC of other biomarkers (p = 0.250). CONCLUSIONS: Plasma levels of Aß oligomers could be assessed using MDS, which might be a simple, noninvasive, and accessible assay for evaluating brain amyloid deposition related to AD pathology.


Subject(s)
Alzheimer Disease/blood , Amyloid beta-Peptides/blood , Peptide Fragments/blood , Aged , Aged, 80 and over , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/diagnostic imaging , Amyloid beta-Peptides/cerebrospinal fluid , Aniline Compounds , Benzothiazoles/pharmacokinetics , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Peptide Fragments/cerebrospinal fluid , Positron-Emission Tomography , Psychiatric Status Rating Scales , Republic of Korea , Retrospective Studies , Thiazoles , tau Proteins/blood , tau Proteins/cerebrospinal fluid
2.
Alzheimers Res Ther ; 9(1): 86, 2017 Oct 17.
Article in English | MEDLINE | ID: mdl-29041968

ABSTRACT

BACKGROUND: A reliable blood-based assay is required to properly diagnose and monitor Alzheimer's disease (AD). Many attempts have been made to develop such a diagnostic tool by measuring amyloid-ß oligomers (AßOs) in the blood, but none have been successful in terms of method reliability. We present a multimer detection system (MDS), initially developed for the detection of prion oligomers in the blood, to detect AßOs. METHODS: To characterize Aß in the blood, plasma was spiked with synthetic amyloid-ß (Aß) and incubated over time. Then, the MDS was used to monitor the dynamic changes of AßO levels in the plasma. RESULTS: Increasing concentrations of AßOs were observed in the plasma of patients with AD but not in the plasma of normal control subjects. The plasma from patients with AD (n = 27) was differentiated from that of the age-matched normal control subjects (n = 144) with a sensitivity of 83.3% and a specificity of 90.0%. CONCLUSIONS: Synthetic Aß spiked into the blood plasma of patients with AD, but that of not elderly normal control subjects, induced dynamic changes in the formation of AßOs over time. AßOs were detected by the MDS, which is a useful blood-based assay with high sensitivity and specificity for AD diagnosis.


Subject(s)
Alzheimer Disease/blood , Amyloid beta-Peptides/blood , Protein Multimerization , Aged , Biomarkers/blood , Blood Chemical Analysis/methods , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoblotting , Male , Middle Aged , Sensitivity and Specificity
3.
Mol Cells ; 35(1): 32-40, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23224239

ABSTRACT

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is regarded as a promising candidate for anticancer therapy due to its selective toxicity to cancer cells. Nevertheless, because of TRAIL resistance in some cancer cells, combined treatment with sensitizing agents is required to enhance the anticancer potential of TRAIL. In this study, we investigated the underlying mechanism of apigenin-induced sensitization of HepG2 cells to TRAIL-induced cell death. Synergistic induction of apoptosis by combination was confirmed by examining the typical morphology changes of apoptosis, PARP-cleavage, and activation of effector caspases. Z-VAD-fmk, a pan-caspase inhibitor, inhibited the enhanced cell death by combined treatment of apigenin and TRAIL, demonstrating that a caspase-dependent pathway is involved in apigenin/TRAIL-mediated apoptosis. In addition, we found that apigenin/ TRAIL co-treatment up-regulates DR5 cell surface expression. The synergistic induction of cell death by the apigenin/ TRAIL combination was significantly attenuated by DR5 blocking chimera antibody. Next, using pharmacological inhibitors, we found that ERK activation is involved in the induction of DR5 expression. Inhibition of ERK1/2 by U0126 significantly decreased the apigenin/TRAIL-induced DR5 expression and apoptosis. Taken together, our results indicate that apigenin can enhance the apoptotic effect of TRAIL via ERK-induced up-regulation of DR5.


Subject(s)
Apigenin/pharmacology , Apoptosis/drug effects , Drug Resistance, Neoplasm/drug effects , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Receptors, TNF-Related Apoptosis-Inducing Ligand/metabolism , TNF-Related Apoptosis-Inducing Ligand/metabolism , Blotting, Western , Butadienes/pharmacology , Caspases/metabolism , Cell Proliferation , Hep G2 Cells , Humans , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Mitogen-Activated Protein Kinase 3/antagonists & inhibitors , Nitriles/pharmacology , Poly(ADP-ribose) Polymerases/metabolism
4.
J Med Food ; 15(8): 691-9, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22784044

ABSTRACT

Platycodin D (PD), a natural compound found in Platycodon grandiflorum, induces apoptotic cell death in various carcinoma cells. One mechanism of PD-mediated cell death is by activation of mitogen-activated protein kinases, as suggested in a recent report. In this study, we further examined upstream signal pathways and the relationship between these signals and reactive oxygen species (ROS). Using immunoblotting assays, we found that PD activated apoptosis signal-regulating kinase 1 (ASK1) through phosphorylation of ASK1 at threonine and dephosphorylation of ASK1 at serine. We also showed that PD caused activation of the endoplasmic reticulum (ER) stress response. This was supported by observations showing that treatment with PD induces phosphorylation of PKR-like ER kinase (PERK) and eukaryotic initiation factor 2 α (eIF 2α), up-regulating expression of glucose-regulated protein 78/immunoglobulin heavy chain binding protein (GRP78/Bip) and CCAAT/enhancer-binding protein homologous protein/growth arrest and DNA damage-inducible gene 153 (CHOP/GADD153) and activation of caspase-4. Furthermore, PD-induced ASK1 and ER stress responses were inhibited by the antioxidant N-acetyl-l-cysteine. These results suggest that ROS play a critical role for activation of ASK1 and ER stress in PD-treated cancer cells.


Subject(s)
Breast Neoplasms/enzymology , Endoplasmic Reticulum Stress , MAP Kinase Kinase Kinase 5/metabolism , Plant Extracts/pharmacology , Platycodon/chemistry , Reactive Oxygen Species/metabolism , Saponins/pharmacology , Triterpenes/pharmacology , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Cell Line, Tumor , Endoplasmic Reticulum Chaperone BiP , Enzyme Activation , Female , Humans , MAP Kinase Kinase Kinase 5/genetics , Mitogen-Activated Protein Kinases/genetics , Mitogen-Activated Protein Kinases/metabolism , Signal Transduction
5.
Mol Cells ; 31(4): 327-35, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21448585

ABSTRACT

Wogonin is a one of the bioactive compounds of Scutellaria baicalensi Georgi which has been shown to have antiinflammatory, anticancer, antiviral and neuroprotective effects. However, the underlying mechanisms by which wogonin induces apoptosis in cancer cells still remain speculative. Here we investigated the potential activation of MAPKs and generation of reactive oxygen species (ROS) by wogonin on MCF-7 human breast cancer cells. These results showed that wogonin induced mitochondria and death-receptor-mediated apoptotic cell death, which was characterized by activation of several caspases, induction of PARP cleavage, change of antiapoptotic/proapoptotic Bcl-2 family member ratios and cleavage of Bid. We also found that generation of ROS was an important mediator in wogonin-induced apoptosis. Further investigation revealed that wogonin activated ERK and p38 MAPKs, which was inhibited by N-acetyl cysteine (NAC), a ROS scavenger, indicating that wogonin-induced ROS are associated with MAPKs activation. These data demonstrate that wogonin may be a novel anticancer agent for treatment of breast cancer.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Extracellular Signal-Regulated MAP Kinases/metabolism , Flavanones/pharmacology , Reactive Oxygen Species/metabolism , Signal Transduction/drug effects , p38 Mitogen-Activated Protein Kinases/metabolism , Apoptosis Regulatory Proteins/metabolism , Breast Neoplasms , Caspase 8/metabolism , Caspase 9/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Enzyme Activation , Female , Humans , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases/metabolism
6.
J Biomed Sci ; 17 Suppl 1: S45, 2010 Aug 24.
Article in English | MEDLINE | ID: mdl-20804622

ABSTRACT

BACKGROUND: Pigmentation in human skin is an important defense mechanism against sunlight or oxidative stress. Despite the protective role of melanin, abnormal hyperpigmentation such as freckles and chloasma sometimes can be serious aesthetic problems. Because of these effects of hyperpigmentation, people have considered the effect of depigmentation. Azelaic acid (AZ) is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. Previously, we showed that AZ inhibited melanogenesis. In this study, we investigated the antimelanogenic activity of combination of AZ and taurine (Tau) in B16F10 mouse melanoma cells. METHODS: The mouse melanoma cell line B16F10 was used in the study. We measured melanin contents and tyrosinase activity. To gain the change of protein expression, we carried out western blotting. RESULTS: We investigated that AZ combined with taurine (Tau) show more inhibitory effects in melanocytes than the treatment of AZ alone. AZ combined with Tau inhibited the melanin production and tyrosinase activity of B16F10 melanoma cells without significant cytotoxicity. Also inhibitory effects after treatment with these combined chemical are stronger than AZ alone on melanogenesis. CONCLUSIONS: These findings indicate that AZ with Tau might play an important role in the regulation of melanin formation and be useful as effective ingredients in antimelanogesis.


Subject(s)
Dicarboxylic Acids/pharmacology , Drug Combinations , Melanins/biosynthesis , Melanocytes/drug effects , Melanoma/drug therapy , Skin Neoplasms/drug therapy , Taurine/pharmacology , Animals , Cell Line, Tumor , Dicarboxylic Acids/metabolism , Dicarboxylic Acids/therapeutic use , Humans , Melanocytes/cytology , Melanocytes/metabolism , Melanoma/pathology , Mice , Microphthalmia-Associated Transcription Factor/metabolism , Monophenol Monooxygenase/metabolism , Pigmentation , Skin Neoplasms/pathology , Taurine/metabolism , Taurine/therapeutic use
7.
J Med Food ; 13(2): 298-305, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20412017

ABSTRACT

Platycodin D (PD), a major constituent isolated from the root of Platycodon grandiflorum, has been suggested to possess anticancer activities, as indicated by its capabilities to induce mitotic arrest and apoptosis in several cancer cells. However, little is known of the underlying action mechanism. This study is the first to investigate the anticancer effect of PD in the human breast cancer cell, MCF-7. Our data showed that PD exhibited marked cell growth inhibition by inducing apoptosis. This induction was associated with activation of caspase-8 and -9 activities and poly(ADP-ribose) polymerase. PD triggered the mitochondrial apoptotic pathway, as indicated by up-regulation of levels of cellular Bax and down-regulation of levels of Bcl-2 and caspase-9 activation. We found that PD induced proteolytic activation of Bid, a member of the proapoptotic Bcl-2 family, implicating PD-induced apoptosis as possibly being functionally linked to a death receptor-mediated pathway. The PD treatment also was accompanied by an increase in cellular generation of reactive oxygen species, indicating that PD-induced apoptosis is likely to be mediated through mitochondrial dysfunction. In addition, we revealed that the mitogen-activated protein kinases, including extracellular signal-regulated kinase 1/2, c-Jun NH(2)-terminal kinase 1/2, and p38, which play important roles in apoptosis, were activated by treatment with PD. These results provide a basic mechanism for the anticancer properties of PD and suggest that PD is a promising candidate for chemotherapy and chemoprevention of breast cancer.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Apoptosis/drug effects , Breast Neoplasms/drug therapy , Phytotherapy , Plant Extracts/pharmacology , Platycodon/chemistry , Saponins/pharmacology , Triterpenes/pharmacology , Antineoplastic Agents, Phytogenic/isolation & purification , Antineoplastic Agents, Phytogenic/therapeutic use , Breast Neoplasms/metabolism , Caspase 8/metabolism , Caspase 9/metabolism , Cell Line, Tumor , Female , Humans , Mitochondria/metabolism , Mitogen-Activated Protein Kinases/metabolism , Plant Extracts/chemistry , Plant Extracts/therapeutic use , Plant Roots , Poly Adenosine Diphosphate Ribose/metabolism , Poly(ADP-ribose) Polymerases/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Reactive Oxygen Species/metabolism , Receptors, Death Domain/metabolism , Saponins/isolation & purification , Saponins/therapeutic use , Triterpenes/isolation & purification , Triterpenes/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...